Q32 Bio Inc. (QTTB)

Q32 Bio Presents Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata in a Late-Breaker at the European Academy of Dermatology and Venereology Congress 2026

Q32 Bio: Durable Hair Regrowth Remains The Goal

Q32 Bio Announces Upcoming Late-Breaking Presentation of Results from Part B of the SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata at the European Academy of Dermatology and Venereology Congress 2026

Q32 Bio Inc. (QTTB) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Q32 Bio Appoints José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D.

Down 23.1% in 4 Weeks, Here's Why Q32 Bio (QTTB) Looks Ripe for a Turnaround

Q32 Bio Inc. $QTTB Stock Position Increased by Atlas Venture Life Science Advisors LLC

Q32 Bio to Participate in Upcoming September Investor Conferences

Wall Street Analysts See an 182.18% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?

Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 185.99%: Read This Before Placing a Bet

Playing The Biotech Breakout With Insiders

Are You Looking for a Top Momentum Pick? Why Q32 Bio (QTTB) is a Great Choice

Q32 Bio: Bempikibart's Progress Keeps Me Bullish

Wall Street Analysts See an 80.12% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?

Q32 Bio Announces Pricing of $200 Million Public Offering of Common Stock and Pre-Funded Warrants

Why Q32 Bio Stock Skyrocketed Today

Q32 Bio: 'Strong Buy' On Solid Bempikibart SIGNAL-AA Study Data And Catalysts

Q32 Bio Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Why Q32 Bio investors should take profits in the stock after 81% rally